Publication:
Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience

Issued Date

2018-12-01

Resource Type

Article

ISSN

0125877X

DOI

10.12932/AP0872

Other identifier(s)

2-s2.0-85059273699

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Asian Pacific journal of allergy and immunology. Vol.36, No.4 (2018), 238-243

Suggested Citation

Theerasuk Kawamatawong, Orapan Poachanukoon, Chalermporn Boonsiri, Atik Saengasapaviriya, Chanchai Sittipunt, Kittipong Maneechotesuwan, Pintip Ngamchanyaporn, Kunchit Piyavechviratana, Praparn Yongjaiyut, Apichart Khanisap, Siwasak Juthong, Warangkana Rithirak, Prapaporn Pornsuriyasak, Chaicharn Pothirat, Watchara Boonsawat Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience. Asian Pacific journal of allergy and immunology. Vol.36, No.4 (2018), 238-243. doi:10.12932/AP0872 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45939

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience

Author(s)

Theerasuk Kawamatawong
 Orapan Poachanukoon
 Chalermporn Boonsiri
 Atik Saengasapaviriya
 Chanchai Sittipunt
 Kittipong Maneechotesuwan
 Pintip Ngamchanyaporn
 Kunchit Piyavechviratana
 Praparn Yongjaiyut
 Apichart Khanisap
 Siwasak Juthong
 Warangkana Rithirak
 Prapaporn Pornsuriyasak
 Chaicharn Pothirat
 Watchara Boonsawat

Other Contributor(s)

Chulalongkorn University
 Khon Kaen University
 Faculty of Medicine, Ramathibodi Hospital, Mahidol University
 Faculty of Medicine, Thammasat University
 Royal Thai Air Force
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Phramongkutklao College of Medicine
 Prince of Songkla University
 Chiang Mai University
 Thai Asthma Council

Abstract

BACKGROUND: To evaluate long-term effectiveness of omalizumab in 'real-life' setting of Thai asthmatic patients. METHODS: We conducted multi-center, observational study in severe asthma patients who received omalizumab in Thailand. Outcomes were asthma exacerbation (hospitalization and ER visit), asthma control test (ACT), and daily ICS dose. Data were evaluated at baseline, 16 Week, and 52 Week. RESULTS: A total of 78 patients received omalizumab treatment (average duration 16.9 months with range 16 weeks-2 years). The mean annualized rate of exacerbations was reduced from baseline (3.79) at Week 16 (3.54) and Week 52 (1.16), (p<0.05), respectively. The mean hospitalization rate was reduced from 0.49 in previous year to 0.15 at Week 16 and 0.19 at Week 52. A reduction in ER visit rates was observed at Week 16 (0.15) and Week 52 (0.97) respectively from baseline (1.44) (p<0.05). The ACT score increased from 15.4 at baseline to 20.6 at Week 16 (p<0.001) and increased to 21.5 at Week 52 (p<0.001). The number of patients with controlled asthma (ACT≥20) increased from 16 of 51 at baseline to 32 of 45 at Week 16 and 25 of 32 at week 52, respectively. The median daily dose of ICS equivalent to fluticasone was reduced from baseline 680 mcg to 500 mcg at Week 52. In all, 22 patients discontinued omalizumab after 1 year. Six patients who discontinued omalizumab were restarted due to relapse of symptoms. CONCLUSIONS: These data confirms the effectiveness of one-year duration of omalizumab treatment in Thai severe asthmatic patients. Furthermore, 27% of patients who discontinued treatment required restarting due to relapse of symptoms.

Keyword(s)

Immunology and Microbiology
 Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/45939

Collections

Scopus 2018